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Simple Summary: We define the transcriptome and secretome of primary LSECs during the progres-
sion of cirrhosis, revealing specific molecular signatures, novel biomarkers and therapeutic targets
for new disease-modifying treatments for patients with advanced chronic liver disease.
Abstract: The poor prognosis of chronic liver disease (CLD) generates the need to investigate the
evolving mechanisms of disease progression, thus disclosing therapeutic targets before development
of clinical complications. Considering the central role of liver sinusoidal endothelial cells (LSECs)
in pre-neoplastic advanced CLD, the present study aimed at investigating the progression of CLD
from an endothelial holistic perspective. RNAseq defined the transcriptome of primary LSECs
isolated from three pre-clinical models of advanced CLD, during the progression of the disease,
and from fresh human cirrhotic tissue. At each stage of the disease, the effects of LSECs secretome
on neighboring cells and proteomic analysis of LSECs-derived extracellular vesicles (EVs) were
also determined. CLD was associated with deep common modifications in the transcriptome of
LSECs in the pre-clinical models. Pathway enrichment analysis showed predominance of genes
related with pro-oncogenic, cellular communication processes, and EVs biogenesis during CLD
progression. Crosstalk experiments revealed endothelial EVs as potent angiocrine effectors. The
proteome of LSECs EVs showed stage-specific signatures, including over-expression of tropomyosin-
1. Proof-of-principle experiments treating cirrhotic HSCs with recombinant tropomyosin-1 suggested
de-activating effects. Our data provide the basis for discovering novel biomarkers and therapeutic
targets for new disease-modifying treatments for patients with advanced CLD.
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1. Introduction
Cirrhosis represents the final pre-neoplastic stage of a group of chronic liver diseases
(CLD) characterized by a complex ensemble of longstanding pathophysiological processes
that alters liver function, architecture and hemodynamics. Cirrhosis constitutes a major
public health problem, accounting for roughly 2 million deaths per year worldwide [1].
In the last decades, many efforts have been made to understand the biological pro-
cesses involved in CLD. Different studies have demonstrated how liver cells phenotype
alterations generate and perpetuate a cascade of mechanisms that altogether lead to the
histological distortion and microcirculatory dysfunction typical of the cirrhotic liver [2–4],
giving rise to portal hypertension (PH), the main non-neoplastic complication of the dis-
ease [5]. Nevertheless, many studies on the underlying mechanisms of CLD and PH have
been made only at the end-stage of the disease, thus ignoring the chronological changes
that promote progression towards cirrhosis. In this context, animal models of liver disease
represent an optimal choice when it comes to study the sequential mechanisms of these
alterations [6].
The liver has four main cellular components: hepatocytes (Hep), liver sinusoidal
endothelial cells (LSECs), hepatic stellate cells (HSCs), and hepatic resident macrophages
(HMΦs). All these cells work in synergy, producing molecules that modulate their differen-
tiation and activity [7] and communicating through paracrine and autocrine mechanisms to
maintain liver homeostasis [8]. In particular, LSECs shape the permeable wall of the sinu-
soids and are actively involved in the dynamic communication process with other hepatic
cells, where they promote vasoactive, inflammatory and immune functions. LSECs are piv-
otal regulators of liver microcirculation and fibrosis, and the maintenance of their specific
phenotype generates a healthy environment in which liver sinusoids and liver function are
preserved [5,9]. In the context of cirrhosis, LSECs exhibit a de-differentiated phenotype
producing a vasoconstrictor, pro-thrombotic, pro-fibrogenic and pro-inflammatory milieu
that negatively affects neighboring cells [10].
Every cell in the organism can produce and secrete biological materials that ultimately
act as inter-cellular signaling mediators. Indeed, the cellular secretome is mainly composed
by free soluble factors and extracellular vesicles (EVs), the latter ones defined as bilayered
nano-sized structures that are able to envelop proteins, lipids and genetic material, shuttling
this biological information between cells [11]. In the field of hepatology, different studies
have evidenced the role of the hepatic secretome as mechanism of cellular communication
within the liver, thus contributing to the pathophysiology of relevant diseases including
alcoholic hepatitis and steatohepatitis [12–15].
Considering that chronological changes that take place within the liver sinusoid during
CLD progression remain mostly unknown, and that LSECs represent a fundamental cell
type regulating hepatocyte function, fibrosis progression and microcirculatory status, the
present study aimed at providing a comprehensive characterization of LSECs phenotype
in human cirrhosis and during cirrhosis progression in experimental models, as a way for
ultimately discover novel therapeutic targets and specific biomarkers of CLD.
2. Materials and Methods
2.1. Animal Models of Liver Disease
To study the biology of the LSECs during CLD progression, twenty-seven male Wistar
Han rats weighing 50–75 g underwent inhalation exposure to carbon tetrachloride (CCl4)
for 2 weeks, 6 weeks or 12–14 weeks (n = 9 per group).These 3 time-points correspond
respectively to acute liver injury, moderate-fibrosis and advanced cirrhosis [16].
To have a more complete approach to the heterogeneity of the CLD we included
two additional models of advanced CLD. Sprague-Dawley male rats were treated with
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thioacetamide (TAA), administered intraperitoneally twice per week for 12 weeks as
described previously [17]. Control rats received saline solution (n = 5 per group). In
addition, secondary biliary cirrhosis was induced in Sprague-Dawley male rats by ligation
of the common bile duct (cBDL) for 4 weeks as described previously [18]. In sham animals,
only surgery was performed without ligation of the common bile duct (n = 5 per group).
Animals were kept at the University of Barcelona Faculty of Medicine facilities with
controlled temperature, humidity and light/dark cycle. Animals were fed ab libitum with
water, supplemented with phenobarbital (0.3 g/L) in the CCl4 model, and standard rodent
food pellets.
In the CCl4 and TAA models, and to diminish acute inflammatory gene response,
LSECs were isolated after 5–7 days of the last toxicant administration. All procedures
were approved by the Laboratory Animal Care and Use Committee of the University of
Barcelona and were conducted in accordance with the European Community guidelines
for the protection of animals used for experimental and other scientific purposes (EEC
Directive 86/609).
2.2. Rat LSECs Isolation and Secretome Fractionation
LSECs were isolated from rats at the three stages of CCl4-CLD progression, from TAA-
cirrhotic rats, from cBDL-cirrhotic rats, and from healthy rats as previously described [19].
For detailed procedures see supplementary information.
After 16 h of culture, LSECs supernatant was collected, centrifuged at 2000× g for
10 min to remove cell debris and apoptotic bodies, pooled (1 pool = 3 rats) and stored
at −80 ◦C until secretome fractionation. Secretome fractionation was performed by se-
quential ultra-centrifugations at increasing g force accelerations as described in previous
protocols [20]. Briefly, after two ultra-centrifugation cycles performed with Sorvall WX Ul-
traseries Centrifuge (ThermoScientific, Waltham, MA, USA) and a P40 ST swinging bucket
(Hitachi, Tokyo, Japan) four fractions were obtained: the non-ultracentrifuged supernatant
(complete secretome, CS), the 10,000 g pellet enriched in large extracellular vesicles (large
EVs, 150–1000 nm diameter), the 100,000 g pellet containing small extracellular vesicles
(small EVs, 50–150 nm diameter) and the final extracellular vesicles-depleted supernatant
containing un-pelleted soluble factors (SF). EVs enriched sub-fractions underwent routine
quality control analysis to determine concentration and quantity following the MISEV 2018
guidelines [21] (see Supplementary Information).
2.3. Human LSECs Isolation
Human liver tissue remnants from liver resections and explants from liver transplantation
surgery were used for LSECs isolation and RNAseq. Non-lesioned non-tumorous liver
tissues from hepatic resections for solitary metastatic colorectal cancer were used as healthy
controls and compared to cirrhotic liver explants from ethanol aetiology (n = 4–5 per group).
Additional donor information is provided in Table S16. All patients received and signed
the informed consent according to the Ethics Committee of the Hospital Clínic de Barcelona
(HCB/2015/0624). hLSECs isolation procedure is detailed in supplementary information.
2.4. LSECs RNA-Sequencing
Human and rat LSECs RNA concentration and quality were assessed with Qubit RNA
HS Assay kit (Thermo Scientific, Eugene, OR, USA) and Agilent RNA 6000 Nano chips (Ag-
ilent Technologies, Waldbronn, Germany), respectively. Samples with RIN > 8 were used
for RNA sequencing. RNA libraries were prepared and amplified using Universal Plus
mRNA-Seq (hLSECs; NuGEN, Leek, Netherlands) or TruSeq Stranded mRNA (rLSECs;
Illumina Inc., San Diego, CA, USA) sample preparation with the corresponding kit. Li-
braries size around 300 bp determined using Agilent High Sensitivity DNA Chip (Agilent
Technologies) were sequenced in an Illumina platform HiSeq2500. Transcriptomic analyses
were performed as previously described [22]. Briefly, STAR program against Homo sapiens
genome hg38 (gencode.v26) or Rattus norvergicus genome (Rnor_6.0) was used for mapping
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the reads followed by the quantification of genes and transcripts with the RSEM program.
We used TMM method and limma-voom transformation to normalize the non-biological
variability. Differential expression between different groups was assessed using moderated
t-statistics [23]. Molecular processes implicated in significant deregulated genes were
analyzed with Ingenuity Pathway Analysis (IPA) software (Qiagen, Hilden, Germany), and
enrichment analyses of deregulated genes were performed using DAVID Bioinformatics
Resources 6.8. All significant deregulated genes were considered when fold-change >
1.5 and p-value < 0.05. RNA sequencing data is available in GEO database: GSE164799
for human and GSE164878 for rat. Data are available at www.shiny.lvbrg.barcelona/lsec
(accessed on 14 May 2021).
2.5. Rat Hepatocytes, HSCs, HMΦ In Vitro Crosstalk
Hepatocytes (5 × 105 cells/mL), HSCs (80% confluence) and HMΦs (80% confluence)
isolated from healthy rats were incubated with LSECs’ secretome fractions from 3 different
biological pools (per each CLD stage) at the following concentrations: CS 550 ng/µL, large
EVs 30 ng/µL, small EVs 30 ng/µL and SF 400 ng/µL. Concentrations were established
considering bibliography and the biological fluctuation of the protein amount of EVs
during the progression of CLD in the rat model. CS and SF fractions were adjusted to the
minimum quantity of protein detected in all pools (110 µg and 80 µg respectively) giving
the final concentrations above mentioned. After 24 h incubation, cells were collected with
RLT buffer containing 10 µL/mL of β-mercaptoethanol (63689–25 ML-F, Sigma, St. Louis,
MO, USA) for subsequent RNA analysis.
2.6. LSECs Secretome Proteomics
Proteomic analysis of LSECs’ secretome was performed at the Proteomic platform of
CIC bioGUNE (Derio, Spain) using a novel hybrid trapped ion mobility spectrometry—
quadrupole time of flight mass spectrometer (tims TOF Pro with PASEF, Bruker Daltonics;
Billerica, MA, USA) coupled online to a nanoElute liquid chromatograph (Bruker) as
detailed in the Supplementary Information.
2.7. Small EVs Internalization Assay
Small EVs from cirrhotic rat LSECs (15 ng/µL) were labelled with the fluorescent
lipophilic dye PKH26 (MINI26–1 KT, Sigma-Aldrich, St Quentin Fallavier, Lyon) according
to manufacturer’s protocol, with minor modifications, and added to the supernatant of
healthy rat HSCs during 1 and 4 h. After the respective incubation periods, HSCs were
washed thrice with PBS and fixed with 2% PFA in PBS and mounted with Fluoromont-G
(E2220-RB70, Southern Biotech, Birmingham, AL, USA) onto microscope slides (J1800
AMNZ, Thermo Scientific). Internalized vesicles were captured with a BX41 microscope
(Olympus, Tokyo, Japan) coupled to a U-RFL-T burner (Olympus). Color channels were
merged and balanced using ImageJ software (Fiji, Madison WI, USA). Cells nuclei were
stained with the NucBlue™ reagent (R37605, Invitrogen, Waltham, MA, USA). Images
were taken at 400× magnification.
2.8. Recombinant Tropomyosin-1 In Vitro Assay
Homology between rat and human TPM1 aminoacidic sequences was determined using
the Protein Blast server (NCBI, Bethesda, MD, USA) resulting in a 94% homology between
sequences. Human recombinant TPM1 (LS-G905, LSBio, Seattle, WA, USA) was used to
assess its activity on primary isolated rat HSCs. HSCs were treated with three different
concentrations of TPM1 (0.1, 1, and 10 µg/mL). After 24 h cells were lysed for RNA extraction
and real time RT-PCR was performed as described in supplementary information.
2.9. Protein Expression Analyses
Protein (immunofluorescence and Western blot) assays are further described in sup-
plementary information.
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2.10. Statistical Analysis
Statistical analysis was performed with Prism 8 (GraphPad Software, La Jolla, CA,
USA). All results are expressed as mean ± S.E.M. Comparisons between groups were
performed with t test or Mann-Whitney U test for non-parametric variables. Differences
were considered significant at a p value < 0.05. Proteome statistics were performed as
detailed in supplementary information.
3. Results
3.1. Rat Cirrhotic LSECs Transcriptome
RNA sequencing of LSECs isolated from cirrhotic CCl4 (12–14 weeks), TAA and cBDL
pre-clinical models of cirrhosis identified 7028 differentially expressed genes (DEG) in
cirrhotic CCl4-LSECs (56.2% up-regulated and 43.8% down-regulated) (Table S1), 3382
DEG in cirrhotic TAA-LSECs (55.6% up-regulated and 44.4% down-regulated) (Table S2),
and 4578 DEG in cBDL-LSECs (55.4% up-regulated and 44.6% down-regulated) (Table S3)
compared with their corresponding healthy LSECs (fold-change > 1.5 and p-value < 0.05)
(Figure 1A).
DEG in each model were then analyzed using the IPA software. The main molecular
processes defined in cirrhotic LSECs de-regulation were cell communication and organization,
pro-oncogenic processes, cell death and survival, immune response, lipid metabolism, and
cellular growth and proliferation, among others (Figure 1B). These results suggested that cell
signaling and communication is key in LSECs pathobiology in cirrhosis development.
Although the number of total DEG was higher in CCl4-LSECs, a large number of
de-regulated genes (801) were commonly shared in the three pre-clinical models (Figure 1C,
Figure S1A,B and Table S4). Additional analysis of the shared DEG in LSECs from experi-
mental models using the DAVID Bioinformatics database [24] distinguished that 140 genes
(17.6%) were involved in cellular components of EVs and their biogenesis (Figure S1C and
Table S5).
3.2. Human Cirrhotic LSECs Transcriptome
The transcriptome of healthy and cirrhotic human CD32 b+ LSECs was analyzed using
bulk RNA sequencing as resumed in Figure 2A. Similarly to the data from pre-clinical
models, the principal component analysis (PCA) defined two clusters of LSECs according to
healthy or cirrhotic phenotype (Figure 2B). After TMM and limma transformation, cirrhotic-
LSECs exhibited 1411 DEG with fold-change > 1.5 and p-value < 0.05 compared with
healthy LSECs (48.8% up-regulated and 51.2% down-regulated). As shown in Figure 2C,
DEG were grouped in two main patterns, healthy or cirrhotic LSECs, demonstrating that
cirrhotic LSECs showed different transcriptomic profile compared to healthy. Top 25 up-
and down-regulated genes are described in Table S6.
Molecular processes analysis of DEG in human cells using IPA software confirmed
“cell communication & organization” as a key process implicated in LSECs capillarization in
cirrhosis (Figure 2D, Left). Indeed, various genes implicated in formation and excretion of
EVs were significantly modulated in cirrhotic hLSECs as shown in the heatmap (Figure 2D,
Right).
Gene ontology analysis between common DEG in human cirrhotic and LSECs isolated
from different pre-clinical models of CLD revealed that a remarkable % of genes defined
extracellular EVs as one of the main cellular components (Supplementary Figure S2). Specif-
ically, human cirrhotic cells shared 71 genes (27.6%) with CCl4-LSECs (Tables S7 and S8),
43 genes (32%) with TAA-LSECs (Tables S9 and S10), 79 genes (28.6%) with cBDL-LSECs
(Tables S11 and S12) and eight genes (24.3%) with the three experimental models of CLD
implicated in EVs components. These transcriptomic analyses further suggested that cell
communication through EVs represents an important process both in human cirrhotic and
animal cirrhotic LSECs capillarization.
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Figure 1. LSECs transcriptome in experimental models of advanced CLD. (A) Transcriptomic profile of LSECs isolated
from CCl4, TAA and cBDL pre-clinical models of chronic liver disease and healthy animals represented as Principal
Component Analysis graphic (Left), and top 25 up- (yellow) and down-regulated (blue) genes represented in heatmaps
(Right). (B) Molecular processes deregulated in cirrhotic LSECs analysed by Ingenuity Pathway Analysis software. (C) Venn
diagram showing the commonly up-regulated (yellow) or down-regulated (blue) genes comparing three pre-clinical models
of CLD (Up), and main molecular processes that define the common differentially expressed genes (Bottom). n = 5–6
independent LSECs isolations per experimental model & healthy. Significant differences are considered in RNAseq when
fold-change > 1.5 and p-value < 0.05.




Figure 2. Transcriptomic profile of human LSECs in advanced CLD. (A) LSECs were isolated from 
human healthy and cirrhotic liver tissue, RNA was sequenced, and differential expression of genes 
was obtained as illustrated. (B) Principal Component Analysis of healthy and cirrhotic human 
LSECs transcriptomic profile. (C) Top 25 of up- (yellow) and down-regulated (blue) human cir-
rhotic LSECs genes depicted in heatmap. (D) Left, molecular processes deregulated in human cir-
rhotic LSECs analysed by Ingenuity Pathway Analysis. Right, heatmap of representative genes 
involved in extracellular vesicles biogenesis and secretion. n = 5 healthy LSECs and n = 4 cirrhotic 
LSECs. Significant differences are considered in RNAseq when fold-change > 1.5 and p-value < 
0.05. 
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Figure 2. Transcriptomic profile of human LSECs in advanced CLD. (A) LSECs were isolated from human healthy and
cirrhotic liver tissue, RNA was sequenced, and differential expression of genes was obtained as illustrated. (B) Principal
Component Analysis of healthy and cirrhotic human LSECs transcriptomic profile. (C) Top 25 of up- (yellow) and down-
regulated (blue) human cirrhotic LSECs genes depicted in heatmap. (D) Left, molecular processes deregulated in human
cirrhotic LSECs analysed by Ingenuity Pathway Analysis. Right, heatmap of representative genes involved in extracellular
vesicles biogenesis and secretion. n = 5 healthy LSECs and n = 4 cirrhotic LSECs. Significant differences are considered in
RNAseq when fold-change > 1.5 and p-value < 0.05.
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3.3. LSECs Transcriptomic Profile during Cirrhosis Progression
Progressive CCl4 administration periods defined three phases of liver injury in the rat
model namely acute (after 2 weeks), fibrotic (6 weeks of administration) and decompen-
sated cirrhosis when rats developed ascites (12–14 weeks) (Figure 3A). LSECs were isolated
from healthy and CCl4-treated rats, the RNA was sequenced, and the transcriptome profile
was analyzed. As shown in Figure 3B, LSECs populations were clustered in four groups
after performing PCA. Transcriptomic analyses showed 9148 DEG (47.5% up-regulated
and 52.5% down-regulated) in LSECs after acute liver injury and 8813 at the stage of liver
fibrosis (48.5% up-regulated and 51.5% down-regulated) compared to healthy-LSECs with
a fold-change > 1.5 and p-value < 0.05 (Figure 3C and Supplementary Table S13). The
results of cirrhotic LSECs are explained above (Section 3.1). We next characterized the
transcriptomic results using IPA in each stage. LSECs showed differential transcriptomic
profile during cirrhosis progression; however, processes implicated in cell communication
and cellular organization are remarkable during all the disease progression, from acute
liver injury until advanced cirrhosis, representing around of 30% of the total molecular pro-
cesses involved in genes de-regulation (Figure 3D). Concretely, we found that several genes
related to molecular complexes and membrane receptors necessary for EVs biogenesis and
exocytosis were differentially expressed in LSECs from the three stages of CCl4 rat model
when compared to healthy LSECs (Figure 3E and Supplementary Table S14). Notably,
genes related with pro-oncogenic processes were incrementally de-regulated during CLD
progression (Figure 3D).
3.4. Effects of LSECs Secretome on Hepatic Neighboring Cells during CLD
Complete secretome (CS), or conditioned media, was obtained from primary LSECs
isolated from rats at the three stages of CLD. To avoid a potential source of exogenous
EVs contamination, we opted for an EVs-depleted FBS and endothelial cell growth sup-
plement was not added to cell cultures, guaranteeing therefore a pure rat LSECs-derived
secretome [21]. Since our interest was to observe the effect of the complete secretome on
neighboring liver cells, LSECs medium was also not complemented with heparin which
could mask EVs receptors on recipient cells [25].
Recipient cells (Hep, HSCs and HMΦs) from healthy rats were incubated with LSECs
CS from acute, fibrotic and cirrhotic stages and the expression of a specific gene set for each
recipient cell type was assessed. Hnf4α, Alb, Slc22 a1 and Slc10 a1 gene expression were
assessed as markers of hepatocyte phenotype [26], Col1α1 and Pdgfrβ as markers of HSCs
activation and collagen producing phenotype [27], Mrc1 and Il-10 for HMΦ pro-resolutive
phenotype and Il-6 and Il-1β for HMΦ pro-inflammatory phenotype [28].
LSECs CSs from specific liver disease stages affected neighboring cells in different
ways. Hepatocytes were minimally affected by LSEC secretomes (Figure 4A) while HSCs
and HMΦs were mostly modulated by CSs proceeding from fibrotic and cirrhotic LSECs.
Indeed, CSs from fibrotic and cirrhotic stages induced an HSC proliferative and collagen
producing phenotype, with no significant changes in αSMA, while those from an acute
stage of CLD were not able to induce the same phenotype switch (Figure 4B). Pro-activation
effects of cirrhotic.
LSEC CS were further confirmed by augmented expression of αSMA protein in HSCs
when incubated for 48 h (Supplementary Figure S3). CS from cirrhotic stage also affected
HMΦs that polarized toward a pro-inflammatory phenotype with no changes in those
genes related to the HMΦs pro-resolutive phenotype (Figure 4C).




Figure 3. LSECs transcriptome during the progression of CLD. (A) Schematic diagram of LSECs 
isolation and RNAseq during CLD progression. (B) Principal Component Analysis representation 
of LSECs isolated at different stages of liver disease. (C) Top 25 up- (yellow) and down-regulated 
(blue) LSECs genes during CLD progression. Deregulated genes have been ordered according to 
the fold-change in cirrhotic LSECs. (D) Molecular processes of LSECs deregulated genes in each 
stage of CLD analysed by Ingenuity Pathway Analysis. (E) Representative deregulated genes dur-
ing CLD progression implicated in the biogenesis and exocytosis of extracellular microvesicles. n = 
5–6 independent LSECs isolations per disease stage. Differences in RNAseq are considered signifi-
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Figure 3. LSECs transcriptome during the progression of CLD. (A) Schematic diagram of LSECs isolation and RNAseq
during CLD progression. (B) Principal Compon nt Analysis re esentation of LSECs isolated at differe t stages of liver
disease. (C) Top 25 up- (yellow) and down-r gulated (blue) LSECs genes during CLD progression. Deregul ted genes have
been ordered according to the fold-change in cirrhotic LSECs. (D) Molecular processes of LSECs deregulated genes in each
stage of CLD analysed by Ingenuity Pathway Analysis. (E) Representative deregulated genes during CLD progression
implicated in the biogenesis and exocytosis of extracellular microvesicles. n = 5–6 independent LSECs isolations per disease
stage. Differences in RNAseq are considered significant when fold-change > 1.5 and p-value < 0.05.




Figure 4. Effects of LSECs secretome on neighbouring liver cells during CLD. mRNA expression of 
specific phenotype markers in hepatocytes (A), HSCs (B) and HMΦs (C) incubated for 24 h with 
the complete secretome (CS) of LSECs isolated at each stage of CLD. mRNA expression of pheno-
type markers in HSCs (D) and HMΦs (E) after 24 h of incubation with the different sub-fractions 
of cirrhotic LSECs secretome: large extracellular vesicles (lEVs), small EVs (sEVs) and soluble fac-
tors (SF), normalized to CS-receiving cells. Results derive from n = 3–5 independent experiments. 
*p < 0.05 and **p < 0.01 on t test (Mann-Whitney U test for non-parametric variables) for differences 
between each group and the CS group. 
Figure 4. Effects of LSECs secretome on neighbouring liver cells during CLD. mRNA expression of specific phenotype
markers in hepatocytes (A), HSCs (B) and HMΦs (C) incubated for 24 h with the complete secretome (CS) of LSECs isolated
at each stage of CLD. mRNA expression of phenotype markers in HSCs (D) and HMΦs (E) after 24 h of incubation with the
different sub-fractions of cirrhotic LSECs secretome: large extracellular vesicles (lEVs), small EVs (sEVs) and soluble factors
(SF), normalized to CS-receiving cells. Results derive from n = 3–5 independent experiments. * p < 0.05 and ** p < 0.01 on t
test (Mann-Whitney U test for non-parametric variables) for differences between each group and the CS group.
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3.5. Effects of LSECs Secretome Sub-Fractions on Liver Cells Phenotype
Once established the disease progression time point at which phenotypic changes
occur in neighboring cells, we wanted to understand whether the observed changes were
due to the entire secretome or to a precise sub-fraction of it. We assessed the activity of
secretome fractions principally on HSCs and HMΦs, since hepatocytes appeared barely
affected by CS.
Although EVs physiological concentration is still unknown, we used the concentration
of EVs normally used in in vitro experiments [29,30]. We also analyzed the concentration
of the large EVs and small EVs fractions, the presence of the principal EVs-related markers
by immunoblot, and finally visualized small EVs by Cryo-TEM (Supplementary Figure S4).
Regarding HSCs, we did not observe a predominant secretome sub-fraction pro-
moting stellate cell activation (Figure 4D), but HMΦs gene expression showed a slightly
greater effect of the SF and large EVs fractions on both the group of genes related to the
pro-inflammatory and pro-resolutive phenotype, suggesting that molecular components
shuttled in these fractions may be prone to rapidly prepare the HMΦ cells machinery to
both inflammatory and resolutive cellular strategies (Figure 4E).
3.6. LSECs Secretome Profile during Cirrhosis Progression
Next, we set out to characterize the components of the LSECs secretome during CLD.
We decided to thoroughly investigate the sub-fraction corresponding to small EVs for
various reasons: first, because of their relevance and growing attention in the field of
Hepatology [11], where LSECs EVs cargo has never been characterized; second, because of
their potential importance in future therapeutic developments and use as disease biomark-
ers [31]; and finally, because we observed a change in the pattern of released EVs by
cirrhotic LSECs, with a decrease in large EVs associated with a concomitant increase in
small EVs levels (Supplementary Figure S4A).
We first confirmed the ability of HSCs to internalize small EVS from cirrhotic LSECs
(Supplementary Figure S5) and subsequently performed a proteomic characterization of the
small EVs LSECs-borne fraction across CLD. The proteomic analysis detected 1034 proteins
of which 345 were submitted to further analysis. Such reduction reflects the selection
criteria used to ensure that the proteins detected were directly coming from cultured rat
LSECs and not from any contamination source (see supplementary information).
Of the 345 proteins, 329 were detected in the healthy group, 213 in the acute injury
group, 303 in the fibrotic group and 275 in the cirrhotic group (Figure 5A, Left). We
evaluated the relative expression of the detected proteins using the Perseus platform [32]
and ran an IPA to assess which biological processes the detected proteins were mostly
related to. Most of the IPA matches were with the categories of cellular organization and
communication, lipid and carbohydrate metabolism and gene and protein expression,
among others (Figure 5A, Right).
Within the analyzed proteins we found various molecules of potential interest such as
histones known to act as DAMPs [33], and elements of the cellular cytoskeleton and cellu-
lar contractile machinery such as tropomyosins, specifically TPM1 and TPM2 (Figure 5B,
Supplementary Table S15). In the case of TPM1, the IPA software grouped it within the cat-
egories of cellular assembly, organization and signaling and the relative expression analysis
with Perseus detected a specific augmented expression of the protein in the cirrhotic stage
while maintaining a moderate expression in the acute and fibrotic stages when compared
with the healthy group (Figure 5C). Consistent with this observation, mRNA and protein
expression of TPM1 was up-regulated in CCl4-cirrhotic LSECs (Figure 5D).




Figure 5. LSECs extracellular vesicles proteomics during CLD progression. (A) Left, number of 
proteins detected in LSECs-derived small EVs at each stage of CLD progression. Right, cellular 
processes of deregulated proteins in cirrhotic LSECs EVs analysed by Ingenuity Pathway Analysis. 
(B) Heatmap of the top up- (yellow) and down-regulated (blue) proteins of LSECs EVs during 
CLD progression and, (C) graphical representation of Tpm1 & 2 gene expression in LSECs EVs 
across CLD. (D) Left, mRNA expression of Tpm1 in healthy and CCl4-cirrhotic LSECs. Values are 
represented in log2 fold-change. Right, western blot representative image of TPM1 in healthy and 
CCl4-cirrhotic LSECs, and corresponding quantification. (E) mRNA expression of depicted genes 
in in vitro activated HSCs and (F) primary isolated cirrhotic CCl4-HSCs exposed to different con-
centrations of recombinant TPM1 for 24 h. Red dot lines represent vehicle-treated cells. Results 
derive from n = 9 isolations (A-B), n = 9 independent samples (C), n = 6 independent isolations (D) 
and n = 3–5 independent experiments (E-F). ###p < 0.001 t test between cirrhotic and healthy 
group; *p < 0.05, **p < 0.01 and ***p < 0.001, t test (Mann-Whitney U test for non-parametric varia-
bles) for differences between each group and the corresponding control group. 
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Figure 5. LSECs extracellular vesicl s proteomics during CLD progression. (A) Left, umber of proteins detected in LSECs-
derived small EVs at each stage of CLD progression. Right, cellular processes of deregulated proteins in cirrhotic LSECs
EVs analysed by Ingenuity Pathway Analysis. (B) Heatmap of the top up- (yellow) and down-regulated (blue) proteins of
LSECs EVs during CLD progression and, (C) graphical representation of Tpm1 & 2 gene expression in LSECs EVs across
CLD. (D) Left, mRNA expression of Tpm1 in healthy and CCl4-cirrhotic LSECs. Values are represented in log2 fold-change.
Right, western blot representative image of TPM1 in healthy and CCl4-cirrhotic LSECs, and corresponding quantification.
(E) mRNA expression of depicted genes in in vitro activated HSCs and (F) primary isolated cirrhotic CCl4-HSCs exposed to
different concentrations of recombinant TPM1 for 24 h. Red dot lines represent vehicle-treated cells. Results derive from
n = 9 isolations (A,B), n = 9 independent samples (C), n = 6 independent isolations (D) and n = 3–5 independent experiments
(E,F). ### p < 0.001 t test between cirrhotic and healthy group; * p < 0.05, ** p < 0.01 and *** p < 0.001, t test (Mann-Wh tney U
test for non-parametric variables) for differences betwe n each group and the corresponding control group.
Cancers 2021, 13, 2688 13 of 17
3.7. Effects of TPM1 on HSCs Phenotype
Considering the differential expression of TPM1 in cirrhotic LSECs small EVs, and
the angiocrine potential of this protein [34], we examined the effects of TPM1 on primary
rat activated HSCs. First, we used in vitro activated HSCs observing a significant decrease
in the gene expression of Col1α1, αSma and Rock1 when treating them with 10 µg/mL,
with no major differences in Pdgfrβ expression when compared to vehicle (Figure 5E). The
same findings were observed in HSCs freshly isolated from cirrhotic rats (Figure 5F). No
signs of HSCs death were observed in response to treatments.
4. Discussion
In the present study, we approached LSECs pathophysiological impact on CLD by
analyzing its phenotypic modifications during the progression to cirrhosis of the liver, the
pre-neoplastic stage of liver cancer [35]. LSECs are known to elicit a pivotal role in the
maintenance and regulation of the liver milieu. Indeed, they possess a unique phenotype
and are involved in the regulation of multiple biological processes such as angiogenesis,
vascular regulation of sinusoidal blood flow, monitoring of gut microbial products and
regulation of the immune response along with HMΦs [36,37]. They constitute the liver’s
first line of defense and the injury-borne endothelial dysfunction has been described as a
main driver of the processes related to HSCs activation and the establishment of PH [5].
Because of this, understanding the grades of LSECs dysfunctionality during the progressive
development of CLD may help at defining novel pathobiological pathways and therapeutic
opportunities for cirrhosis.
To pursue this aim we first characterized the transcriptome of LSECs isolated from
three widely used pre-clinical models of advanced CLD, then, validated these pre-clinical
results with data from primary human cirrhotic LSECs and, finally, developed a progressive
liver injury model to mimic the chrono-biological alterations of CLD we wanted to investi-
gate. Transcriptomic analysis revealed valuable data regarding the genes and the molecular
pathways de-regulated in advanced CLD, disclosing those related with oncogenic pro-
cesses and cellular communication as the two major descriptors of the rat capillarized
liver endothelium. The same molecular processes defined the transcriptome of human
CD32 b+ LSECs isolated from patients with CLD compared to controls. Detailed analysis
of de-regulated genes in our transcriptomic data revealed that most of the deregulated
genes both in human and rat cirrhotic LSECs were related to communication processes,
specifically with the biogenesis and exocytosis of EVs. This observation agrees with pre-
vious studies demonstrating that LSECs paracrinally communicate with other resident
liver cells being able, for example, to regulate HSCs phenotype [9,38,39]. Moreover, our
RNAseq data coincide with recent works characterizing the liver endothelium at single cell
level [38–40]. Indeed, molecular processes and cellular component analyses of previous
human and mouse transcriptomic data confirmed that vesicle-mediated transport and cell
communication and organization molecular processes are markedly induced in cirrhotic
LSECs (Supplementary Figure S6), overall validating our observations and reinforcing the
importance of LSECs-mediated cross-talk within the liver milieu.
We then wondered whether LSECs-derived EVs could convey specific biological infor-
mation that changes along the progression of CLD and that may have a stage-dependent
influence on the phenotype of neighboring liver cells. To test this hypothesis, we used
a pre-clinical model of CLD, where stage-specific changes in LSECs phenotype and se-
cretome can be investigated. Particularly, the transcriptome and secretome of the liver
endothelium was characterized across the progression of CLD using the CCl4 pre-clinical
model of cirrhosis. This animal model has been used to characterize stage-specific changes
in CLD disease [16] and probably represents the mostly used experimental model to in-
vestigate the pathophysiology of CLD and its clinical complications. Molecular pathways
analysis of deregulated genes in each stage of the disease revealed that approximately one
third of them relate to cellular interaction/communication, confirming the importance
of LSEC angiocrine activity during chronic liver injury. On the other hand, fluctuation
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of certain pathways along cirrhosis progression was observed, including a reduction in
immune response and an increment in pro-oncogenic genes, which indeed deserves future
investigations that are out of the scope of the present work.
Analysis of the genes involved in LSEC angiocrine capacity, specifically in the biogen-
esis of EVs, showed a stage-dependent up-regulation in the ESCRT-dependent pathway
(Mvb12 a, Mvb12 b), lipid-rafts structures such as Flot2, the tetraspanins Cd9 and Cd81,
and the Rab3 a small GTPase responsible for migration of EVs to the plasma membrane
and subsequent exocytosis, among others. Although such up-regulations were not accom-
panied by an enhanced vesicle secretion by LSECs, the crosstalk experiments on HSCs and
HMΦs with the endothelial secretome fractions, suggested that the content rather than
the quantity might be involved in the phenotype regulation of recipient cells. Indeed, it
has been shown that EVs cargo is representative of the cell physiological stage and their
content is able to sensitize the recipient cells reprogramming their behavior within the liver
milieu [41].
We therefore characterized the protein content of the endothelial small EVs sub-
fraction during the progression of CLD. This proteomic analysis revealed a group of
potentially interesting proteins but, due to their implication in contractility processes and
as a proof-of-concept study, we focused on tropomyosins and specifically on TPM1 which
expression across the CLD was lightly up-regulated and finally spiked in the cirrhotic
stage. TPM1 expression has been previously found in activated HSC colocalizing with
αSMA in liver tissue samples from rat livers [42], and has also been detected in serum
and liver tissue from patients [43], where it has been proposed as potential biomarker of
cirrhosis. Despite the abovementioned studies, our results suggest that TPM1 may have a
protective-like effect on activated HSCs.
We admit limitations in our study such as the use of immunomagnetism to isolate
human LSECs, which may induce selection of certain cellular sub-populations. Although
CD32 b has been previously used as marker for LSECs isolation [44,45], we applied gene
set enrichment analysis to corroborate the phenotypic concordances between our cells
and the endothelial cells described in [39] using single cell analysis. The results of these
analyses confirmed that CD32 b+ cells used in our study were mostly enriched in LSECs.
The number of human donors included in the study may be considered low, nevertheless
it is larger than previous works and, importantly, both the molecular processes and the
gene ontology analyses of human and rat cirrhotic LSECs validated the transcriptomic
profile involved in human LSECs deregulation. We also admit that the results from
the proof-of-concept experiments using TPM1 may be controversial. The real impact of
endothelial-derived TPM1 embedded in small EVs on neighboring cells in a multi-cellular
milieu, and its underlying mechanisms, remains conjectural. Future desirable studies will
help to clarify the specific role of LSECs-derived EVs in CLD pathophysiology, and their
possible role as novel biomarkers of endothelial dysfunction in disease.
On the other hand, we do believe that our work adds significant pieces of relevant
data to the liver vascular pathobiology field. The analysis of LSECs transcriptome in three
mostly used pre-clinical models of CLD provides data pointing to the singularity of each
model, the commonly shared de-regulated pathways and, importantly, their similarity to
the human liver endothelium in cirrhosis. It is important to highlight that deep analysis
of our data demonstrated that certain genes and molecular pathways de-regulated in
cirrhotic human LSEC are mirrored or not in a particular animal model, thus providing
essential information for a better use of pre-clinical models of disease in order to improve
the translatability of pre-clinical findings to the real clinical scenario [6]. Our data also
complement previous transcriptomic works characterizing the transcriptome of sinusoidal
cells in healthy [40,41,46] and CLD [40,47] scenarios, nevertheless this is the first time that
the dynamic changes of LSECs transcriptome have been investigated across CLD, compared
to human cells, and holistically explored considering LSECs secretome, altogether helping
to further understand the pathobiology of liver endothelial dysfunction in cirrhosis.
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5. Conclusions
In conclusion, the present study is the first to provide a comprehensive transcriptomic
analysis of LSECs, and to characterize the secretory machinery of this cell type, during
the progression of CLD. Although experimental in nature, we believe that our data will
serve as conceptual basis for the discovery of novel biomarkers and therapeutic targets for
the treatment of patients with cirrhosis and other liver diseases coursing with endothelial
dysfunction.
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